AGM update and CEO transition
Destiny’s AGM provided a summary of an eventful year that included the licensing of its lead Phase 3-ready asset NTCD-M3 and a successful fundraising. With attention turning to the partnering of its second Phase 3-ready product XF-73, the backdrop to new anti-infectives continues to be supportive.The AGM was preceded by the announcement of Destiny’s CEO’s departure: his interim replacement with a handover period is Dr Debra Barker, whom we have met previously. We regard Dr Barker as very competent and level-headed, plus there is the benefit of a listed anti-infectives company being led by someone with significant anti-infective drug development experience.
Focus turns to its second Phase 3-ready product – XF-73 for the prevention of post-operative staphylococcal infections – and the once ‘left for dead’ anti-infectives space in big pharma is undergoing a renaissance. XF-73 has been developed without finding bacteria that are resistant to it and is being developed to prevent infections. This contrasts with Xacduro and gepotidacin which will only be prescribed to patients with a resistant infection.
Our fair value for Destiny Pharma plc remains at £254.7m, or 279 pence per share.
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.